立体定向体部放射治疗前列腺寡转移癌的研究进展
Advances in Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer
DOI: 10.12677/acm.2026.1641266, PDF,    科研立项经费支持
作者: 赵 惠*#：山东第二医科大学附属医院泌尿外科，山东 潍坊；荆小许*, 解浩然, 姜睿哲, 马云航, 蒋承烨：山东第二医科大学临床医学院，山东 潍坊；邱书浩：湖南中医药大学中医学院，湖南 长沙
关键词: 前列腺寡转移癌；立体定向体部放射治疗；转移灶定向治疗；系统治疗；Oligometastatic Prostate Cancer； Stereotactic Body Radiotherapy； Metastasis-Directed Therapy； Systemic Therapy
摘要: 前列腺寡转移癌(oligometastatic prostate cancer, OMPC)是介于局限期与广泛转移期之间的特殊疾病阶段，具有转移负荷有限、生物学行为相对可控的特点。随着前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描等高灵敏度成像技术的出现，转移病灶得以在早期阶段被检测和精确定位，从而实现更精确的疾病分层和治疗决策。现有研究表明，立体定向体部放射治疗(stereotactic body radiotherapy, SBRT)在前列腺寡转移癌中具有较高的局部控制率和较低的毒性反应，能够有效清除可见病灶并在一定程度上延缓雄激素剥夺治疗(androgen deprivation therapy, ADT)治疗，改善患者生活质量。同时，在系统治疗基础上联合SBRT，也可进一步提高生存率并延长影像学无进展生存期，显示出一定的协同作用，本综述旨在系统梳理SBRT在前列腺寡转移癌中提高局部控制率，延缓系统治疗及改善生存结局等方面的研究进展，明确其在综合治疗中的临床价值，为优化治疗策略及筛选获益人群提供理论依据，为前列腺寡转移癌治疗的优化策略提供理论依据和新的研究方向。
Abstract: Oligometastatic prostate cancer (OMPC) represents a distinct clinical state between localized disease and widespread metastatic progression, characterized by a limited metastatic burden and relatively controllable biological behavior. With the advent of highly sensitive imaging modalities such as prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT), metastatic lesions can be detected and precisely localized at an early stage, enabling more accurate disease stratification and therapeutic decision-making. Accumulating evidence indicates that stereotactic body radiotherapy (SBRT) achieves high rates of local control with a favorable toxicity profile in patients with OMPC. By effectively ablating visible metastatic lesions, SBRT can delay the initiation or escalation of androgen deprivation therapy (ADT), thereby postponing treatment-related adverse effects and improving patients’ quality of life. Moreover, when integrated with systemic therapy, SBRT may further enhance survival outcomes and prolong imaging-based progression-free survival, suggesting a potential synergistic effect within a multimodal treatment framework. This review aims to systematically summarize the current evidence regarding the role of SBRT in OMPC, with particular emphasis on its impact on local control, postponement of systemic therapy, and improvement of survival outcomes. By clarifying the clinical value of SBRT within comprehensive treatment strategies, this review seeks to provide a theoretical basis for optimizing therapeutic approaches and identifying patient subgroups most likely to benefit, as well as to outline future directions for research in the management of oligometastatic prostate cancer.
文章引用：赵惠, 荆小许, 邱书浩, 解浩然, 姜睿哲, 马云航, 蒋承烨. 立体定向体部放射治疗前列腺寡转移癌的研究进展[J]. 临床医学进展, 2026, 16(4): 436-445. https://doi.org/10.12677/acm.2026.1641266

参考文献

[1] Parker, C.C., James, N.D., Brawley, C.D., Clarke, N.W., Hoyle, A.P., Ali, A., et al. (2018) Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. The Lancet, 392, 2353-2366. [Google Scholar] [CrossRef] [PubMed]
[2] Kothari, G., Ost, P., Cheung, P., Blanchard, P., Tree, A.C., van As, N.J., et al. (2019) Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer. Current Oncology Reports, 21, Article No. 43. [Google Scholar] [CrossRef] [PubMed]
[3] Weichselbaum, R.R. and Hellman, S. (2011) Oligometastases revisited. Nature Reviews Clinical Oncology, 8, 378-382. [Google Scholar] [CrossRef] [PubMed]
[4] Sonpavde, G. (2017) The Biology of Prostate Cancer Metastases. Current Opinion in Urology, 27, 542-546. [Google Scholar] [CrossRef] [PubMed]
[5] Alberto, M., Yim, A., Papa, N., Siva, S., Ischia, J., Touijer, K., et al. (2022) Role of PSMA Pet-Guided Metastases-Directed Therapy in Oligometastatic Recurrent Prostate Cancer. Frontiers in Oncology, 12, Article ID: 929444. [Google Scholar] [CrossRef] [PubMed]
[6] Müller, P.J., Dietlein, M., Kobe, C., Heidenreich, A. and Drzezga, A. (2022) Oligometastatic Disease in Biochemical Recurrence of Prostate Cancer: Prevalence on PSMA PET/CT and Consecutive Metastasis-Directed Therapy—Experience at a Tertiary Referral Center. Nuklearmedizin-NuclearMedicine, 61, 314-324. [Google Scholar] [CrossRef] [PubMed]
[7] Phillips, R., Shi, W.Y., Deek, M., Radwan, N., Lim, S.J., Antonarakis, E.S., et al. (2020) Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncology, 6, 650-659. [Google Scholar] [CrossRef] [PubMed]
[8] Habl, G., Straube, C., Schiller, K., Duma, M.N., Oechsner, M., Kessel, K.A., et al. (2017) Oligometastases from Prostate Cancer: Local Treatment with Stereotactic Body Radiotherapy (SBRT). BMC Cancer, 17, Article No. 361. [Google Scholar] [CrossRef] [PubMed]
[9] Viani, G.A., Arruda, C.V., Hamamura, A.C., Faustino, A.C., Freitas Bendo Danelichen, A. and Guimarães, F.S. (2020) Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Recurrence. American Journal of Clinical Oncology, 43, 73-81. [Google Scholar] [CrossRef] [PubMed]
[10] Zhang, B. and Leech, M. (2020) A Review of Stereotactic Body Radiation Therapy in the Management of Oligometastatic Prostate Cancer. Anticancer Research, 40, 2419-2428. [Google Scholar] [CrossRef] [PubMed]
[11] Bouman-Wammes, E.W., van Dodewaard-De Jong, J.M., Dahele, M., Cysouw, M.C.F., Hoekstra, O.S., van Moorselaar, R.J.A., et al. (2017) Benefits of Using Stereotactic Body Radiotherapy in Patients with Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]Fluoromethylcholine Pet/ct. Clinical Genitourinary Cancer, 15, e773-e782. [Google Scholar] [CrossRef] [PubMed]
[12] Werensteijn-Honingh, A.M., Wevers, A.F.J., Peters, M., Kroon, P.S., Intven, M., Eppinga, W.S.C., et al. (2021) Progression-Free Survival in Patients with 68Ga-PSMA-PET-Directed SBRT for Lymph Node Oligometastases. Acta Oncologica, 60, 1342-1351. [Google Scholar] [CrossRef] [PubMed]
[13] Le Guevelou, J., Cuccia, F., Flippot, R., Ferrera, G., Terlizzi, M., Zilli, T., et al. (2024) The Current Landscape of Stereotactic Body Radiation Therapy for Metastatic Castration-Resistant Prostate Cancer. Prostate Cancer and Prostatic Diseases, 28, 546-556. [Google Scholar] [CrossRef] [PubMed]
[14] Chen, H., Badellino, S., Biswas, T., Dagan, R., Erler, D., Foote, M., et al. (2022) Conditional Survival of Patients with Extracranial Oligometastatic Treated with Stereotactic Body Radiation Therapy: An International Consortium Study. International Journal of Radiation Oncology, Biology, Physics, 114, 902-909. [Google Scholar] [CrossRef] [PubMed]
[15] Massaro, M., Facondo, G., Vullo, G., Aschelter, A.M., Rossi, A., De Sanctis, V., et al. (2021) Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer. Frontiers in Oncology, 11, Article ID: 695136. [Google Scholar] [CrossRef] [PubMed]
[16] Hellman, S. and Weichselbaum, R.R. (1995) Oligometastases. Journal of Clinical Oncology, 13, 8-10. [Google Scholar] [CrossRef] [PubMed]
[17] Hofman, M.S., Lawrentschuk, N., Francis, R.J., Tang, C., Vela, I., Thomas, P., et al. (2020) Prostate-Specific Membrane Antigen PET-CT in Patients with High-Risk Prostate Cancer before Curative-Intent Surgery or Radiotherapy (Propsma): A Prospective, Randomised, Multicentre Study. The Lancet, 395, 1208-1216. [Google Scholar] [CrossRef] [PubMed]
[18] Ottaiano, A., Santorsola, M., Circelli, L., Trotta, A.M., Izzo, F., Perri, F., et al. (2023) Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives. Cancers, 15, Article 1827. [Google Scholar] [CrossRef] [PubMed]
[19] Gundem, G., Van Loo, P., Kremeyer, B., Alexandrov, L.B., Tubio, J.M.C., Papaemmanuil, E., et al. (2015) The Evolutionary History of Lethal Metastatic Prostate Cancer. Nature, 520, 353-357. [Google Scholar] [CrossRef] [PubMed]
[20] Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., et al. (2012) Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. New England Journal of Medicine, 366, 883-892. [Google Scholar] [CrossRef] [PubMed]
[21] Gandaglia, G., Fossati, N., Montorsi, F. and Briganti, A. (2017) Reply to Pascal Mouracade’s Letter to the Editor Re: Giorgio Gandaglia, Nicola Fossati, Armando Stabile, Et Al. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-Institution Series with Long-Term Follow-Up. Eur Urol 2017;72:289-92. Do the Data Violate Kaplan-Meier Assumptions? European Urology, 72, e31. [Google Scholar] [CrossRef] [PubMed]
[22] Salomon, L., Levrel, O., de La Taille, A., et al. (2002) Seminal Vesicle Invasion after Radical Prostatectomy: Study of Risk Factors for Progression. Progres en Urologie: Journal De l’Association Francaise D’urologie et de la Societe Francaise D’urologie, 12, 621-627.
[23] Oliai, C., Lanciano, R., Sprandio, B., Yang, J., Lamond, J., Arrigo, S., et al. (2012) Stereotactic Body Radiation Therapy for the Primary Treatment of Localized Prostate Cancer. Journal of Radiation Oncology, 2, 63-70. [Google Scholar] [CrossRef] [PubMed]
[24] Jackson, W.C., Silva, J., Hartman, H.E., Dess, R.T., Kishan, A.U., Beeler, W.H., et al. (2019) Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of over 6,000 Patients Treated on Prospective Studies. International Journal of Radiation Oncology, Biology, Physics, 104, 778-789. [Google Scholar] [CrossRef] [PubMed]
[25] Gawish, A., Abdullayev, N., El-Arayedh, S., Röllich, B., Ochel, H. and Brunner, T.B. (2022) Metabolic Response after 68Ga-PSMA-PET/CT-Directed IGRT/SBRT for Oligometastases Prostate Cancer. Clinical and Translational Oncology, 25, 987-994. [Google Scholar] [CrossRef] [PubMed]
[26] Yan, M., Moideen, N., Bratti, V.F. and Moraes, F.Y.d. (2020) Stereotactic Body Radiotherapy (SBRT) in Metachronous Oligometastatic Prostate Cancer: A Systematic Review and Meta-Analysis on the Current Prospective Evidence. The British Journal of Radiology, 93, Article 20200496. [Google Scholar] [CrossRef] [PubMed]
[27] Deijen, C.L., Vrijenhoek, G.L., Schaake, E.E., Vogel, W.V., Moonen, L.M.F., Pos, F.J., et al. (2021) PSMA-11-PET/CT versus Choline-PET/CT to Guide Stereotactic Ablative Radiotherapy for Androgen Deprivation Therapy Deferral in Patients with Oligometastatic Prostate Cancer. Clinical and Translational Radiation Oncology, 30, 1-6. [Google Scholar] [CrossRef] [PubMed]
[28] Kwon, D.H., Shakhnazaryan, N., Shui, D., Hong, J.C., Mohamad, O., de Kouchkovsky, I., et al. (2023) Serial Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer Detected by Novel Pet-Based Radiotracers. Urologic Oncology: Seminars and Original Investigations, 41, 145.e7-145.e15. [Google Scholar] [CrossRef] [PubMed]
[29] See, A.W., Conway, P., Frydenberg, M., Haxhimolla, H., Costello, A.J., Moon, D., et al. (2024) Five‐Year Outcomes of Fractionated Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer from the transform Phase II Trial. International Journal of Cancer, 155, 1248-1256. [Google Scholar] [CrossRef] [PubMed]
[30] Zhao, X., Wang, T., Ye, Y., Li, J., Gao, X. and Zhang, H. (2022) Stereotactic Body Radiotherapy (SBRT) versus Androgen Deprivation Therapy (ADT) for Oligometastatic Prostate Cancer: Protocol for a Prospective Randomised Control Clinical Trial. BMJ Open, 12, e051371. [Google Scholar] [CrossRef] [PubMed]
[31] Kneebone, A., Hruby, G., Ainsworth, H., Byrne, K., Brown, C., Guo, L., et al. (2018) Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-Specific Membrane Antigen Positron Emission Tomography. European Urology Oncology, 1, 531-537. [Google Scholar] [CrossRef] [PubMed]
[32] Xu, C., Zhao, X., Ju, X., Shen, Y., Qu, M., Ye, Y., et al. (2022) Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China. Frontiers in Oncology, 12, Article ID: 879310. [Google Scholar] [CrossRef] [PubMed]
[33] Niazi, T., Saad, F., Tisseverasinghe, S., Koul, R., Thibault, I., Chung, P.W.M., et al. (2025) Metastases-Directed Therapy in Addition to Standard Systemic Therapy in Oligometastatic Castration-Resistant Prostate Cancer in Canada (GROUQ-PCS 9): A Multicentre, Open-Label, Randomised, Phase 2 Trial. The Lancet Oncology, 26, 1158-1167. [Google Scholar] [CrossRef] 
[34] Ahmed, K.A., Barney, B.M., Davis, B.J., Park, S.S., Kwon, E.D. and Olivier, K.R. (2013) Stereotactic Body Radiation Therapy in the Treatment of Oligometastatic Prostate Cancer. Frontiers in Oncology, 2, Article ID: 215. [Google Scholar] [CrossRef] [PubMed]
[35] Baron, D., Pasquier, D., Pace-Loscos, T., Vandendorpe, B., Schiappa, R., Ortholan, C., et al. (2023) Systemic Therapy Escalation after Stereotactic Body Radiation Therapy for Oligometastatic Hormone-Sensitive Prostate Cancer. Clinical and Translational Radiation Oncology, 43, Article 100673. [Google Scholar] [CrossRef] [PubMed]
[36] Marvaso, G., Volpe, S., Pepa, M., Augugliaro, M., Corrao, G., Biffi, A., et al. (2021) Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-Analysis of Prospective Studies. European Urology Open Science, 27, 19-28. [Google Scholar] [CrossRef] [PubMed]
[37] Leeman, J.E., Shin, K., Chen, Y., Mak, R.H., Nguyen, P.L., D’Amico, A.V., et al. (2023) Acute Toxicity Comparison of Magnetic Resonance‐Guided Adaptive versus Fiducial or Computed Tomography‐Guided Non‐Adaptive Prostate Stereotactic Body Radiotherapy: A Systematic Review and Meta‐Analysis. Cancer, 129, 3044-3052. [Google Scholar] [CrossRef] [PubMed]
[38] Hang, Z., Huang, Y., Song, A. and Sun, Z. (2025) Radiotherapy Elicits Immunogenic Cell Death and Metabolic Shifts in the Tumor Microenvironment: Implications for Immunotherapy. International Journal of Medical Sciences, 22, 3277-3291. [Google Scholar] [CrossRef] [PubMed]
[39] Vaes, R.D.W., Hendriks, L.E.L., Vooijs, M. and De Ruysscher, D. (2021) Biomarkers of Radiotherapy-Induced Immunogenic Cell Death. Cells, 10, Article 930. [Google Scholar] [CrossRef] [PubMed]
[40] Nickols, N.G., Ganapathy, E., Nguyen, C., Kane, N., Lin, L., Diaz-Perez, S., et al. (2021) The Intraprostatic Immune Environment after Stereotactic Body Radiotherapy Is Dominated by Myeloid Cells. Prostate Cancer and Prostatic Diseases, 24, 135-139. [Google Scholar] [CrossRef] [PubMed]
[41] Zhu, M., Yang, M., Zhang, J., Yin, Y., Fan, X., Zhang, Y., et al. (2021) Immunogenic Cell Death Induction by Ionizing Radiation. Frontiers in Immunology, 12, Article ID: 705361. [Google Scholar] [CrossRef] [PubMed]
[42] Zhang, Z., Liu, X., Chen, D. and Yu, J. (2022) Radiotherapy Combined with Immunotherapy: The Dawn of Cancer Treatment. Signal Transduction and Targeted Therapy, 7, Article No. 258. [Google Scholar] [CrossRef] [PubMed]
[43] Palermo, B., Bottero, M., Panetta, M., Faiella, A., Sperduti, I., Masi, S., et al. (2023) Stereotactic Ablative Radiation Therapy in 3 Fractions Induces a Favorable Systemic Immune Cell Profiling in Prostate Cancer Patients. OncoImmunology, 12, Article 2174721. [Google Scholar] [CrossRef] [PubMed]
[44] Xu, K., Gu, T., Su, K., Liu, X., He, B., He, J., et al. (2025) Stereotactic Body Radiation Therapy (SBRT) Increases Anti-Pd-1 Antitumor Activity by Enhancing the Tumor Immune Microenvironment in Mice with Metastatic Hepatocellular Carcinoma. Discover Oncology, 16, Article No. 1081. [Google Scholar] [CrossRef] [PubMed]
[45] Francolini, G., Allegra, A.G., Detti, B., Di Cataldo, V., Caini, S., Bruni, A., et al. (2023) Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO). Journal of Clinical Oncology, 41, 5561-5568. [Google Scholar] [CrossRef] [PubMed]
[46] Mercier, C., Claessens, M., De Troyer, B., Debacker, T., Fransis, K., Vandeursen, H., et al. (2022) Survival Outcomes and Pattern of Relapse after SABR for Oligometastatic Prostate Cancer. Frontiers in Oncology, 12, Article ID: 863609. [Google Scholar] [CrossRef] [PubMed]
[47] Pastorello, E., Nicosia, L., Cuccia, F., Olivari, L., Fiorini, M., Giaj Levra, N., et al. (2023) PSMA-PET/CT-Based Stereotactic Body Radiotherapy (SBRT) in the Treatment of Uncomplicated Non-Spinal Bone Oligometastases from Prostate Cancer. Cancers, 15, Article 2800. [Google Scholar] [CrossRef] [PubMed]
[48] Mohan, R., Kneebone, A., Eade, T., Hsiao, E., Emmett, L., Brown, C., et al. (2023) Long-Term Outcomes of SBRT for PSMA PET Detected Oligometastatic Prostate Cancer. Radiation Oncology, 18, Article No. 127. [Google Scholar] [CrossRef] [PubMed]

为你推荐